AIV-007 is a novel formulation of a multi-kinase inhibitor combined with AiViva’s JEL™ Technology designed for prolonged drug release. AIV-007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFβ1 mRNA expression and TGFβ1 levels to prevent and inhibit cell proliferation.
AIV-007 is currently being developed for neovascular macular degeneration (nAMD) and benign prostatic hyperplasia (BPH). In nonclinical in vivo studies for nAMD, AIV-007 demonstrated ocular safety in several animal models and effects in the reduction of neovascularization and fibrosis. In nonclinical studies for BPH, AIV-007 demonstrated effects in reduction of prostate hyperplasia both in disease regression and prophylactic treatment. Moreover, AIV007 achieved pharmacologically meaningful drug concentrations in the prostate while systemic exposure was limited.
AiViva is on track to start clinical trials in nAMD in 2020.